论文部分内容阅读
目的：考察法乐通治疗晚期绝经后乳腺癌的疗效及其不良反应。方法：法乐通一线治疗每日一次６０ｍｇ口服，二线治疗每日一次１２０ｍｇ口服。结果：共６０例，有效率１８３％。一线治疗１８例，有效率３３３％。二线治疗４２例，有效率１１９％。淋巴结和骨转移疗效较好，肝转移、肺转移及胸壁转移也有一定疗效。一线治疗较二线治疗、未用内分泌治疗较曾用内分泌治疗、绝经时间长（≥１０年）较绝经时间短（＜１０年）以及疗后无瘤间期长（≥５年）较疗后无瘤间期短（＜５年）疗效好，不良反应轻微，主要为恶心、纳差。结论：法乐通是治疗晚期绝经后乳腺癌有效和安全的抗雌激素抗肿瘤新药。
Objective: To investigate the efficacy and adverse reactions of Farreton in the treatment of advanced postmenopausal breast cancer. Methods: Farewell first-line treatment once daily 60mg oral, second-line treatment once daily 120mg oral. Results: A total of 60 cases, an effective rate of 18 to 3%. First-line treatment of 18 cases, an effective rate of 33. 3%. The second-line treatment of 42 cases, an effective rate of 11.9%. Lymph nodes and bone metastases have good curative effects, and liver metastases, lung metastases, and chest wall metastases also have a certain effect. First-line treatment was more endocrine therapy than second-line treatment, no endocrine therapy was used, menopause was longer (≥10 years) than short-term menopause (<10 years), and no tumor-free period was longer (≥5 years) than after treatment. The short-term (<5 years) interstitial period has good curative effects and minor adverse reactions, mainly nausea and anorexia. Conclusion: Farreton is an effective and safe anti-estrogen antitumor drug for the treatment of advanced postmenopausal breast cancer.